The Cronos Group

Company Snapshot

Founded: 2012
Entity Type: Public
Employees: 459
Region: Canada
Revenue: $117.6 Millions
Revenue Year: 2024
Headquarter: Toronto, Canada
Key Geographics: North America, Middle East, and Other countries
Corporate Address: 4491 Concession Road 12 Stayner, Ontario Canada Tel. +1-416-504-0004 www.thecronosgroup.com

Company Overview

Founded in 2013 as PharmaCan, the Cronos Group develops and scales up cannoboids. It is a leader in applications using synthetic biology of the cannabis plant.

In September 2018, the Cronos Group formed a partnership with Gingko Bioworks to produce rare cannoboids at scale. The agreement accelerated Crono’s goal of being a cannabinoid company versus only a cannabis company.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

The Cronos Group In Reports

Cannabis: The Medicinal Use

BCC Research Market Report says The global cannabis market is segmented on the basis of components, types, substitutes, and regulations in different countries.

Company's Business Segments

  • Cannabis : The company offers a variety of cannabis and cannabinoid products for medical and adult-use markets across Canada, Israel, Germany, Australia, and the UK.

Applications/End User Industries

  • Adult-Use (Recreational) Cannabis
  • Medical Cannabis
  • Health and Wellness
  • Biotechnology (Cultured Cannabinoids)
AI Sentiment